Tolerability of initiation doses of once-monthly paliperidone palmitate in patients with recently diagnosed schizophrenia in an acute treatment trial

Therapeutic Advances in Psychopharmacology

Volumn 1, Issue 4, 2011, Pages 111-124

  Bossie, Cynthia A ^a   fu, Dong Jing ^a   Sliwa, Jennifer Kern ^a   Alphs, Larry ^a   ma, yi Wen ^b  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

paliperidone palmitate; recent diagnosis; schizophrenia; tolerability; treatment

Indexed keywords

PALIPERIDONE;

ADULT; AGITATION; ANXIETY DISORDER; ARTICLE; BODY WEIGHT; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG TOLERABILITY; DYSKINESIA; DYSTONIA; EJACULATION DISORDER; FEMALE; HUMAN; HYPERKINESIA; INJECTION SITE PAIN; LIBIDO DISORDER; MALE; PARKINSONISM; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SIDE EFFECT; TREMOR;

EID: 84998044463     PISSN: 20451253     EISSN: 20451261     Source Type: Journal    
DOI: 10.1177/2045125311413006     Document Type: Article

References (60)

1. Allison D.B. Casey D.E. (2001) Antipsychotic-induced weight gain: A review of the literature. J Clin Psychiatry 62(Suppl. 7): 22–31.
2. Alphs L. Bossie C. Sliwa J.K. Ma Y.-W. Haskins J.T. (2009) Paliperidone palmitate: Clinical response in subjects with schizophrenia with recent diagnosis vs longer-time since diagnosis. American Psychiatric Association [Poster NR6-027] 16–21 May, San Francisco, CA.
3. Alvarez-Jimenez M. Gonzalez-Blanch C. Crespo-Facorro B. Hetrick S. Rodriguez-Sanchez J.M. Perez-Iglesias R. et al. (2008) Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: A systematic critical reappraisal. CNS Drugs 22: 547–562.
4. Barnes T.R. Leeson V.C. Mutsatsa S.H. Watt H.C. Hutton S.B. Joyce E.M. (2008) Duration of untreated psychosis and social function: 1-year follow-up study of first-episode schizophrenia. Br J Psychiatry 193: 203–209.
5. Bleuler M. (1972) The Schizophrenic Disorders: Long-term Patient and Family Studies London: Yale University Press.
6. Bobes J. Gilbert J. Ciudad A. Alvarez E. Canas F. Carrasco J.-L. et al. (2003) Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients. Prog Neuropsychopharmacol Biol Psychiatry 27: 473–481.
7. Canuso C.M. Bossie C.A. Amatniek J. Turkoz I. Pandina G. Cornblatt B. (2010) Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia. Early Interv Psychiatry 4: 64–78.
8. Chue P. Emsley R. (2007) Long-acting formulations of atypical antipsychotics: Time to reconsider when to introduce depot antipsychotics. CNS Drugs 21: 441–448.
9. Coldham E.L. Addington J. Addington D. (2002) Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand 106: 286–290.
10. Davidson M. Emsley R. Kramer M. Ford L. Pan G. Lim P. et al. (2007) Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): Results of a 6-week, randomized, placebo-controlled study. Schizophr Res 93(1–3): 117–130.
11. Emsley R. Medori R. Koen L. Oosthuizen P.P. Niehaus D. Rabinowitz J. (2008) Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: A preliminary study. J Clin Psychopharmacol 28: 210–213.
12. Falloon I.R. Kydd R.R. Coverdale J.H. Laidlaw T.M. (1996) Early detection and intervention for initial episodes of schizophrenia. Schizophr Bull 22: 271–282.
13. Fleischhacker W.W. Meise U. Gunther V. Kurz M. (1994) Compliance with antipsychotic drug treatment: Influence of side effects. Acta Psychiatr Scand 89(Suppl.): 11–15.
14. Francey S.M. Nelson B. Thompson A. Parker A.G. Kerr M. Macneil C. (2010) Who needs antipsychotic medication in the earliest stages of psychosis? A reconsideration of benefits, risks, neurology and ethics in the era of early intervention. Schizophr Res 119: 1–10.
15. Gilmer T.P. Dolder C.R. Lacro J.P. Folsom D.P. Lindamer L. Garcia P. et al. (2004) Adherence to treatment with antipsychotic medication and healthcare costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 161: 692–699.
16. Gopal S. Gassmann-Mayer C. Palumbo J. Samtani M.N. Shlwach R. Alphs L. (2010) Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia. Curr Med Res Opin 26: 377–387.
17. Gupta S. Frank B. Madhusodanan S. (2001) Risperidone-associated galactorrhea in a male teenager. J Am Acad Child Adolesc Psychiatry 40: 504–505.
18. Harrigan S.M. McGorry P.D. Krstev H. (2003) Does treatment delay in first-episode psychosis really matter? Psychol Med 33: 97–110.
19. Hough D. Gopal S. Vijapurkar U. Lim P. Morozova M. Eerdekens M. (2010) Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled study. Schizophr Res 116: 107–117.
20. Hough D. Lindenmayer J.P. Gopal S. Melkote R. Lim P. Herben V. et al. (2009) Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 33: 1022–1031.
21. Janno S. Holi M. Tuisku K. Wahlbeck K. (2004) Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients. Am J Psychiatry 161: 160–163.
22. Kane J. Canas F. Kramer M. Ford L. Gassmann-Mayer C. Lim P. et al. (2007) Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial. Schizophr Res 90: 147–161.
23. Kasper S. (1999) First-episode schizophrenia: the importance of early intervention and subjective tolerability. J Clin Psychiatry 60(Suppl. 23): 5–9.
24. Keith S.J. Kane J. (2003) Partial compliance and patient consequences in schizophrenia: Our patients can do better. J Clin Psychiatry 64: 1308–1315.
25. Kelly D.L. Conley R.R. Carpenter W.T. (2005) First-episode schizophrenia: A focus on pharmacological treatment and safety considerations. Drugs 65: 1113–1138.
26. Kim B. Lee S.H. Choi T.K. Suh S.Y. Kim Y.W. et al. (2008) Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting. Prog Neuropsychopharmacol Biol Psychiatry 32: 1231–1235.
27. Kramer M. Simpson G. Maciulis V. Kushner S. Vijapurkar U. Lim P. et al. (2007) Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: A randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 27: 6–14.
28. Lieberman J.A. Drake R.E. Sederer L.I. Belger A. Keefer R. Perkins D. et al. (2008) Science and recovery in schizophrenia. Psychiatr Serv 59: 487–496.
29. Lieberman J.A. Perkins D. Belger A. Chakos M. Jarskog F. Boteva K. et al. (2001) The early stages of schizophrenia: Speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 50: 884–897.
30. Llorca P.M. Chereau I. Bayle F.J. Lancon C. (2002) Tardive dyskinesias and antipsychotics: A review. Eur Psychiatry 17: 129–138.
31. Marder S.R. Kramer M. Ford L. Eerdekens E. Lim P. Eerdekens M. et al. (2007) Efficacy and safety of paliperidone extended-release tablets: Results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry 62: 1363–1370.
32. Marshall M. Lewis S. Lockwood A. Drake R. Jones P. Croudace T. (2005) Association between duration of untreated psychosis and in cohorts of first-episode outcome patients – a systematic review. Arch Gen Psychiatry 62: 975–983.
33. Masi G. Cosenza A. Mucci M. (2001) Prolactin levels in young children with pervasive developmental disorders during risperidone treatment. J Child Adolesc Psychopharmacol 11: 389–394.
34. McGlashan T.H. Fenton W.S. (1993) Subtype progression and pathophysiologic deterioration in early schizophrenia. Schizophr Bull 19: 71–84.
35. McGlashan T.H. Miller T.J. Woods S.W. (2001) Pre-onset detection and intervention research in schizophrenia psychoses: Current estimates of benefit and risk. Schizophr Bull 27: 563–570.
36. McGorry P. (2005) and Group IEPAW. International clinical practice guidelines for early psychosis. Br J Psychiatry 187(Suppl. 48): S120–S124.
37. McGorry P.D. Killackey E. Yung A.R. (2007) Early intervention in psychotic disorders: Detection and treatment of the first episode and the critical early stages. Med J Aust 187(7 Suppl.): S8–S10.
38. McGorry P.D. Killackey E. Yung A.R. (2008) Early intervention in psychosis: Concepts, evidence and future directions. World Psychiatry 7: 148–156.
39. Menzin J. Boulanger L. Friedman M. Mackell J. Lloyd J.R. (2003) Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatr Serv 54: 719–723.
40. Merlo M.C.G. Hofer H. Gekle W. Berger G. Ventura J. Panhuber I. et al. (2002) Risperidone, 2 mg/day vs 4 mg/day, in first-episode, acutely psychotic patients: Treatment efficacy and effects on fine motor functioning. J Clin Psychiatry 63: 885–991.
41. Muench J. Carey M. (2001) Diabetes mellitus associated with atypical antipsychotic medications: New case report and review of the literature. J Am Board Fam Pract 14: 278–282.
42. Mueser K.T. McGurk S.R. (2004) Schizophrenia. Lancet 363: 2063–2072.
43. Nasrallah H. Gopal S. Gassmann-Mayer C. Quiroz J.A. Lim P. Eerdekens M. et al. (2010) A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology 35: 2072–2082.
44. Pandina G. Lindenmayer J.P. Lull J. Lim P. Gogal S. Herben V. et al. (2010) A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol 30: 235–244.
45. Parellada E. Andrezina R. Milanova V. Glue P. Masiak M. St John Turner M. et al. (2005) Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable. J Psychopharmacol 19: 5–14.
46. Perkins D.O. Gu H. Boteva K. Liberman J.A. (2005) Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: A critical review and meta-analysis. Am J Psychiatry 162: 1785–1804.
47. Robinson D. Woerner M.G. Alvir J.M. Bilder R. Goldman R. Geisler S. et al. (1999) Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 56: 241–247.
48. Salimi K. Jarskog L.F. Lieberman J.A. (2009) Antipsychotic drugs for first-episode schizophrenia: A comparative review. CNS Drugs 23: 837–855.
49. Sanger T.M. Lieberman J.A. Tohen M. Grundy S. Beasley C. Jr Tollefson G.D. (1999) Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry 156: 79–87.
50. Schooler N. Rabinowitz J. Davidson M. Emsley R. Harvey P.D. Kopala L. et al. (2005) Risperidone and haloperidol in first-episode psychosis: A long-term randomized trial. Am J Psychiatry 162: 947–953.
51. Seretti A. De Ronchi D. Lorenzi C. Berardi D. (2004) New antipsychotics and schizophrenia: A review of efficacy and side effects. Curr Med Chem 11: 343–358.
52. Tandon R. Nasrallah H.A. Keshavan M.S. (2009) Schizophrenia, ‘just the facts’ 4: Clinical features and conceptualization. Schizophr Res 110: 1–23.
53. Tschoner A. Eng J. Laimer M. Kaser S. Rettenbacher M. Fleischhacker W.W. et al. (2007) Metabolic side effects of antipsychotic medication. Int J Clin Pract 61: 1356–1370.
54. Ucok A. Polar A. Genc A. Caku S. Turan N. (2004) Duration of untreated psychosis may predict acute treatment response in first-episode schizophrenia. J Psychiatr Res 38: 163–168.
55. Valenstein M. Blow F.C. Copeland L.A. McCarthy J.R. Zeber J.E. Gillon L. et al. (2004) Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull 30: 255–264.
56. Weiden P.J. Schooler N.R. Weedon J.C. Elmouchtari A. Sunakawa A. Goldfinger S.M. (2009) A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: Initial adherence outcome. J Clin Psychiatry 70: 1397–1406.
57. Woods S.W. Martin A. Spector S.G. McGlashan T.H. (2002) Effects of development on olanzapine-associated adverse events. J Am Acad Child Adolesc Psychiatry 41: 439–446.
58. World Health Organization. (2007) Mental Health and Substance Abuse. Facts and Figures. Schizophrenia: Youth's Greatest Disabler. Available at: http://www.searo.who.int/en/section1174/section1199/Section 1567_6755.htm (accessed May 2011).
59. Wudarsky M. Nicolson R. Hamberger S.D. Spechler L. Gochman P. Bedwell J. et al. (1999) Elevated prolactin in pediatric patients on typical and atypical antipsychotics. J Child Adolesc Psychopharmacol 9: 239–245.
60. Wyatt R.J. (1991) Early intervention with neuroleptics may decrease the long-term morbidity of schizophrenia. Schizophr Res 5: 201–202.